The Misuse of Drugs Regulations 2001

• (1) Subject to paragraph (3) and regulation 21, every person authorised by or under regulation 5 or 8 to supply any drug specified in Schedule 1 or 2 shall comply with the following requirements, that is to say—

• (a) he shall, in accordance with the provisions of this regulation and of regulation 20, keep a register and shall enter therein in chronological sequence subject to subparagraph (f), using the headings specified in subparagraphs (d) and (e), particulars of every quantity of a drug specified in Schedule 1 or 2 obtained by him and of every quantity of such a drug supplied (whether by way of administration or otherwise) by him whether to persons within or outside Great Britain;

• (b) he shall use a separate register or separate part of the register for entries made in respect of each class of drugs, and each of the drugs specified in paragraphs 1 and 3 of Schedule 1 and paragraphs 1, 3 and 6 of Schedule 2 together with its salts and any preparation or other product containing it or any of its salts shall be treated as a separate class, so however that any stereoisomeric form of a drug or its salts shall be classed with that drug.

• (d) The headings in respect of entries made for drugs obtained are—

• (i) Date supply received;

• (ii) Name and address from whom received;

• (iii) Quantity received.

• (e) The headings in respect of entries made for drugs supplied are—

• (i) Date supplied;

• (ii) Name/Address of person or firm supplied;

• (iii) Details of authority to possess – prescriber or licence holder’s details;

• (iv) Quantity supplied;

• (v) Person collecting Schedule 2 controlled drug (patient/ patient’s rep/ healthcare professional) and if healthcare professional, name and address;

• (vi) Was proof of identity requested of patient/ patient’s rep (Yes/No);

• (vii) Was proof of identity of person collecting provided (Yes/No).

• (f) The headings at subparagraph (e)(v) to (vii) apply only in respect of drugs specified in Schedule 2.

• (2) Entries made in respect of drugs obtained and drugs supplied may be made on the same page or on separate pages in the register.

• (2A) Subject to regulation 20(e), nothing in paragraph (1) shall prevent the use of a register to record additional information to that required or allowed under those provisions.

• (3) The foregoing provisions of this regulation shall not have effect in relation to—

• (a) in the case of a drug supplied to him for the purpose of destruction in pursuance of regulation 6(2) or (3), a practitioner or pharmacist;

• (b) a person licensed under regulation 5 to supply any drug, where the licence so directs; or

• (c) the senior registered nurse, acting senior registered nurse or registered midwife, for the time being in charge of a ward, theatre or other department in a hospital, care home or prison.

Requirements as to registers

20

Any person required to keep a register under regulation 19 shall comply with the following requirements, that is to say—

• (a) in the separate register or separate part of the register used for each class of drug, a separate page shall be used in respect of each strength and form of that drug and the head of each such page shall specify the class of the drug, its strength and form;

• (b) every entry required to be made under regulation 19 in such a register shall be made on the day on which the drug is obtained or, as the case may be, on which the transaction in respect of the supply of the drug by the person required to make the entry takes place or, if that is not reasonably practicable, on the day next following that day;

• (c) no cancellation, obliteration or alteration of any such entry shall be made, and a correction of such an entry shall be made only by way of marginal note or footnote which shall specify the date on which the correction is made;

• (d) every such entry and every correction of such an entry shall be made in ink or otherwise so as to be indelible or shall be in a computerised form in which every such entry is attributable and capable of being audited and which is in accordance with best practice guidance endorsed by the Secretary of State under section 2 of the National Health Service Act 1977;

• (e) such a register shall not be used for any purpose other than purposes related to these Regulations;

• (f) a separate register shall be kept in respect of each premises at which the person required to keep the register carries on his business or occupation, but subject to that not more than one register shall be kept at one time in respect of each class of drugs in respect of which he is required to keep a separate register, so, however, that a separate register may, with the approval of the Secretary of State, be kept in respect of each department of the business carried on by him;

• (g) every such register in which entries are currently being made shall be kept at the premises to which it relates and, where the register is in computerised form, be accessible from those premises.

Record-keeping requirements in respect of drugs in Schedules 1 and 2

21

• (1) Where a drug specified in Schedule 2 is supplied in accordance with regulation 8(5)(a)(i) to any person on a ship, an entry in the official log book required to be kept under the Merchant Shipping Act 1995 or, in the case of a ship which is not required to carry such an official logbook, a report signed by the master of the ship, shall, notwithstanding anything in these Regulations, be a sufficient record of the supply if the entry or report specifies the drug supplied and, in the case of a report, it is delivered as soon as may be to a superintendent at a Marine Office established and maintained under the Merchant Shipping Act 1995.

• (2) Where a drug specified in Schedule 2 is supplied in accordance with regulation 8(5)(b)(i) to a person on an offshore installation, an entry in the installation logbook required to be maintained under the Offshore Installations (Logbooks and Registration of Death) Regulations 1972 which specifies the drug supplied shall, notwithstanding anything in these Regulations, be a sufficient record of the supply.

• (3) A midwife authorised by regulation 11(1) to have any drug specified in Schedule 2 in her possession shall—

• (a) on each occasion on which she obtains a supply of such a drug, enter in a book kept by her and used solely for the purposes of this paragraph the date, the name and address of the person from whom the drug was obtained, the name of the person to whom it is to be administered or supplied, the amount obtained and the form in which it was obtained; and

• (b) on administering or supplying such a drug to a patient, enter in the said book as soon as practicable the name and address of the patient, the name of the person to whom it was administered or supplied, the amount administered and the form in which it was administered.

Record-keeping requirements in respect of drugs in Schedules 1 and 2

22

• (1) Every person who is authorised under regulation 5 or 9(1)(c ) to produce any drug specified in Schedule 3 or 4 shall make a record of each quantity of such a drug produced by him.

• (2) Every person who is authorised by or under any provision of the Act to import or export any drug specified in Schedule 3 shall make a record of each quantity of such a drug imported or exported by him.

• (3) Every person who is authorised under regulation 9(4) to supply any drug specified in Schedule 4 shall make a record of each quantity of such a drug imported or exported by him.

• (4) Paragraph (2) shall not have effect in relation to a person licensed under the Act to import or export any drug where the licence so directs.

• (5) Every person who is authorised by or under any provision of the Act to have in his possession or to destroy, or cause to be destroyed, the substance specified in paragraph 5 of Part 1 of Schedule 4 shall make a record of each quantity of such drug possessed or destroyed.

• (6) Paragraph (5) shall not have effect in relation to—

• (a) a patient to whom the substance specified in paragraph 5 of Part 1 of Schedule 4 has been prescribed;

• (b) a constable when acting in the course of his duty as such;

• (c) a person engaged in the business of a carrier when acting in the course of that business;

• (d) a person engaged in the business of a postal operator (within the meaning of Part 3 of the Postal Services Act 2011) when acting in the course of that business;

• (e) an officer of customs and excise when acting in the course of his duty as such;

• (f) a person engaged in the work of any laboratory to which the substance specified in paragraph 5 of Part 1 of Schedule 4 has been sent for forensic examination when acting in the course of his duty as a person so engaged; and

• (g) a person engaged in conveying the substance specified in paragraph 5 of Part 1 of Schedule 4 to a person who may lawfully have that substance in his possession.

Preservation of registers, books and other documents

23

• (1) All registers and books kept in pursuance of regulation 19 or 21(3) shall be preserved for a period of two years from the date on which the last entry therein is made.

• (2) Every record made in pursuance of regulation 22 shall be preserved for a period of two years from the date on which the record was made.

• (3) Every ... ... veterinary prescription on which a controlled drug is supplied in pursuance of these Regulations , and every prescription (other than a health prescription) on which a controlled drug specified in Schedules 4 or 5 is so supplied, shall be preserved for a period of two years from the date on which the last delivery under it was made.

• (4) Every prescription (other than a health prescription or a veterinary prescription) on which a controlled drug other than a drug specified in Schedule 4 or 5 is supplied shall be sent to the relevant National Health Service agency in accordance with arrangements specified by that agency.

Preservation of records relating to drugs in Schedules 3 and 5

24

• (1) A producer of any drug specified in Schedule 3 or 5 and a wholesale dealer in any such drug shall keep every invoice or other like record issued in respect of each quantity of such a drug obtained by him and in respect of each quantity of such a drug supplied by him.

• (2) A person who is authorised under regulation 9(4)(a) to supply any drug specified in Schedule 3 shall keep every invoice or other like record issued in respect of each quantity of such a drug obtained by him and in respect of each quantity of such a drug supplied by him.

• (3) A retail dealer in any drug specified in Schedule 3, a person in charge or acting person in charge of a hospital, organisation providing ambulance services or care home and a person in charge of a laboratory shall keep every invoice or other like record issued in respect of each quantity of such a drug obtained by him and in respect of each quantity of such a drug supplied by him.

• (4) A retail dealer in any drug specified in Schedule 5 shall keep every invoice or other like record issued in respect of each quantity of such a drug obtained by him.

• (5) Every invoice or other record which is required by this regulation to be kept in respect of a drug specified in Schedule 3 shall contain information sufficient to identify the date of the transaction and the person by whom or to whom the drug was supplied.

• (6) Every document kept in pursuance of this regulation (other than a health prescription) shall be preserved for a period of two years from the date on which it is issued, except that the keeping of a copy of the document made at any time during the said period of two years shall be treated for the purposes of this paragraph as if it were the keeping of the original document.

Exempt products

25

Nothing in regulations 19 to 24 shall have effect in relation to any exempt product.

Furnishing of information with respect to controlled drugs

26

• (1) The persons specified in paragraph (2) shall on demand made by the Secretary of State or by any person authorised in writing by the Secretary of State in that behalf—

• (a) furnish such particulars as may be requested in respect of the producing, obtaining or supplying by him of any controlled drug or in respect of any stock of such drugs in his possession;

• (b) for the purpose of confirming any such particulars, produce any stock of such drugs in his possession;

• (c) produce any register, book or document required to be kept under these Regulations relating to any dealings in controlled drugs which is in his possession.

• (1A) For the purposes of paragraph (1)(c), the Secretary of State or any person authorised in writing by the Secretary of State in that behalf may request that a register which is kept in computerised form be produced by sending a copy of it, in computerised or other form, to the appropriate person.

• (2) The persons referred to in paragraph (1) are—

• (a) any person authorised by or under these Regulations to produce any controlled drug;

• (b) any person authorised by or under any provision of the Act to import or export any controlled drug;

• (c) a wholesale dealer;

• (d) a retail dealer;

• (e) a practitioner;

• (f) the person in charge or acting person in charge of a hospital, organisation providing ambulance services or care home;

• (g) a person who is in charge of a laboratory;

• (h) a person who is authorised under regulation 9(4)(a) to supply any controlled drug.

• (i) a supplementary prescriber;

• (j) a nurse independent prescriber

• (k) a registered chiropodist or registered podiatrist;

• (l) a paramedic independent prescriber;

• (m) a therapeutic radiographer independent prescriber.

• (3) Nothing in this regulation shall require the furnishing of personal records which a person has acquired or created in the course of his profession or occupation and which he holds in confidence; and in this paragraph “personal records” means documentary and other records concerning an individual (whether living or dead) who can be identified from them and relating to his physical or mental health.

Destruction of controlled drugs

27

• (1) No person who is required by any provision of, or by any term or condition of a licence having effect under, these Regulations to keep records with respect to a drug specified in Schedule 1, 2, 3 or 4 shall destroy such a drug or cause such a drug to be destroyed except in the presence of and in accordance with any directions given by a person authorised (whether personally or as a member of a class) for the purposes of this paragraph by the Secretary of State or, subject to paragraph (1A), an accountable officer (hereafter in this regulation referred to as an “authorised person”).

• (1A) An accountable officer shall not be an authorised person.

• (2) An authorised person may, for the purposes of analysis, take a sample of a drug specified in Schedule 1, 2, 3 or 4 which is to be destroyed.

• (3) Where a drug specified in Schedule 1, 2, 3 or 4 is destroyed in pursuance of paragraph (1) by or at the instance of a person who is required by any provision of, or by any term or condition of a licence having effect under, these Regulations to keep a record in respect of the obtaining or supply of that drug, that record shall include particulars of the date of destruction and the quantity destroyed and shall be signed by the authorised person in whose presence the drug is destroyed.

• (4) Where the master or owner of a ship or installation manager of an offshore installation has in his possession a drug specified in Schedule 2 which he no longer requires, he shall not destroy the drug or cause it to be destroyed but shall dispose of it to a constable, or to a person who may lawfully supply that drug to him.

• (5) Nothing in paragraph (1) or (3) shall apply to any person who is required to keep records only by virtue of regulation 22(2), (3) or (5) or 24(3).

• (6) Nothing in paragraph (1) or (3) shall apply to the destruction of a drug which has been supplied to a practitioner or pharmacist for that purpose in pursuance of regulation 6(2) or (3).

Revocations

28

• (1) The regulations specified in Schedule 7 are hereby revoked.

• (2) Notwithstanding paragraph (1), any register, record, book, prescription or other document required to be preserved under regulation 23 or 24 of the Misuse of Drugs Regulations 1985 shall be preserved for the same period of time as if these Regulations had not been made.

• (3) In the case of a prescription issued before the coming into force of these Regulations, regulation 16(1) shall have effect as if—

• (a) in the case of a prescription containing a controlled drug other than a drug to which the provisions of regulation 15 of the Misuse of Drugs Regulations 1985 applied at the time the prescription was issued, sub-paragraphs (a) and (b) of that paragraph were omitted; and

• (b) in any other case, for the said sub-paragraphs (a) and (b) there were substituted the words “ unless the prescription complies with the provisions of the Misuse of Drugs Regulations 1985 relating to prescriptions ”.

SCHEDULE 1 — CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 18, 19, 20, 23, 26 AND 27

1

The following substances and products, namely -

• (a)

• Adinazolam (1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine)

• AP-237 (1-[4-([2E]-3-phenyl-2-propen-1-yl)-1-piperazinyl]-1-butanone) (bucinnazine)

• AP-238 (1-[2,6-dimethyl-4-[2E]-3-phenyl-2-propen-1-yl]-1-piperazinyl-1-propanone)

• Azaprocin (1-[3-[(E)-3-phenyl-2-propen-1-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]propan-1-one)

• Bentazepam (5-phenyl-1,3,6,7,8,9-hexahydro-2H-[1]benzothieno[2,3-e][1,4]diazepin-2-one)

• N-Benzyl-ethylphenidate

• Bretazenil (tert-butyl-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a]-pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate)

• Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

• Brorphine

• Bufotenine

• Butonitazene

• Cannabinol

• Cannabinol derivatives not being—dronabinol or its stereoisomers; orthe substance specified in paragraph 10 of Schedule 5

• Cannabis (not being the substance specified in paragraph 5 of Part 1 of Schedule 4) and cannabis resin

• Cathinone

• 4’-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Clobromazolam (8-bromo-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

• Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)

• Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Clonitazene

• Coca leaf

• Concentrate of poppy-straw

• Cumyl-PeGaClone

• Desalkylgidazepam (7-bromo-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Deschloroclotizolam (2-chloro-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)

• Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)

• 3,4-Dichloroethylphenidate

• 3,4-Dichloromethylphenidate (3,4-DCMP)

• Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Difludiazepam (7-chloro-5-(2,6-difluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one)

• [2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone

• 3–Dimethylheptyl–11–hydroxyhexahydrocannabinol

• Diphenidine

• Ephenidine

• Ethyleneoxynitazene

• Ethylnaphthidate

• Ethylphenidate

• Eticyclidine

• Etizolam

• Etodesnitazene (etazene)

• Etonitazene

• Etryptamine

• Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

• Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Flubromazolam(8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)

• Flubrotizolam (2-bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2f][1,2,4]triazolo[4,3a][1,4]diazepine)

• Fluclotizolam (2-chloro-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)

• Fluetizolam (2-ethyl-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)

• Flunitazene

• Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

• 4-Fluoroethylphenidate

• 4-Fluoromethylphenidate

• Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Fungus (of any kind) which contains psilocin or an ester of psilocin

• Gidazepam (7-bromo-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-1-acetic acid hydrazide)

• [9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate

• 9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol

• 3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Isopropylphenidate (IPP or IPPD)

• Isotonitazene

• Khat

• Lysergamide

• Lysergide and otherN-alkyl derivatives of lysergamide

• Meclonazepam(5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Mescaline

• Methcathinone

• Methoxyphenidine (1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine) (methoxphenidine)

• Methylclonazepam (5-(2-chlorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one)

• 4-Methylmethylphenidate

• Methylmorphenate

• Methylnaphthidate (HDMP-28)

• N-methyl-1-(thiophen-2-yl)propan-2-amine (methiopropamine or MPA)

• Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)

• Metodesnitazene (metazene)

• Metonitazene

• Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

• Norfludiazepam (7-chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)

• para-methyl-AP-237 (1-[4-[2E]-3-(4-methylphenyl)-2-propen-1-yl]-1-piperazinyl-1-butanone)

• para-nitroazaprocin (1-[3-[(E)-3-(4-nitrophenyl)-2-propen-1-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl)propan-1-one)

• Propylphenidate

• Protonitazene

• ...

• Psilocin

• Pyrazolam(8-Bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)

• Raw opium

• Rilmazafone (5-([(2-aminoacetyl)amino]methyl)-1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-N,N-dimethyl-1H-1,2,4-triazole-3-carboxamide)

• Rolicyclidine

• Tenocyclidine

• Thionordazepam (7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-thione)

• (6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ALD-52)

• 4-Bromo-2,5-dimethoxy-a-methylphenethylamine

• 4’-Chloro-deschloroalprazolam (6-(4-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)

• 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)

• N-Desethyl etonitazene

• N-Desethylisotonitazene

• N-Desethyl protonitazene

• 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)

• 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47,700)

• (6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD)

• (6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD)

• (6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD)

• N,N-Diethyltryptamine

• 2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol

• 2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin-9-yl}methanone (LSZ)

• N,N-Dimethyltryptamine

• 2,5-Dimethoxy-a,4-dimethylphenethylamine

• N-Hydroxy-tenamphetamine

• 4-Methyl-aminorex

• 2-Methyl-AP-237 (1-[2-methyl-4-[2E]-3-phenyl-2-propen-1-yl]-1-piperazinyl-1-butanone)

• 4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4’-DMAR)

• N-Piperidinyl-etonitazene (etonitazepipne)

• N-Pyrrolidino-etonitazene (etoniazepyne)

• N-Pyrrolidino protonitazene

• (b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—

• (i) by substitution at the nitrogen atom of the sidechain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;

• (ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;

• (iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;

• (iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent;

• (c) the following phenethylamine derivatives, namely—

• Allyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol

• 2-Amino-1-(3,4-dimethoxyphenyl)ethanol

• Benzyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• 4-Bromo-b,2,5-trimethoxyphenethylamine

• N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine

• Cyclopropylmethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine

• 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine

• 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine

• 2-(1,4-Dimethoxy-2-naphthyl)ethylamine

• 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine

• N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine

• 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine

• 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine

• a,a-Dimethyl-3,4-methylenedioxyphenethylamine

• a,a-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine

• Dimethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine

• 4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine

• 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine

• 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine

• 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

• 2-Methoxyethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

• 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

• b-Methoxy-3,4-methylenedioxyphenethylamine

• 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine

• 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine

• 2-(a-Methyl-3,4-methylenedioxyphenethylamino)ethanol

• a-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine

• N-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

• O-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

• a-Methyl-4-(methylthio)phenethylamine

• b,3,4,5-Tetramethoxyphenethylamine

• b,2,5-Trimethoxy-4-methylphenethylamine

• (d) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, anN-alkylphenethylamine,a-methylphenethylamine, anN-alkyl-a-methylphenethylamine,a-ethylphenethylamine, or anN-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;

• (e) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -

• (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

• (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;

• (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;

• (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;

• (v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;

• (vi) by replacement of theN-propionyl group by another acyl group;

• (f) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say—

• (i) by replacement of the l-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;

• (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;

• (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;

• (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;

• (v) by formation of an N-oxide or of a quaternary base.

• (g) 1–benzylpiperazine or any compound (not being a compound for the time being specified in Schedule 4) structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways—

• (i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;

• (ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups;

• (h) Any compound structurally derived from 3–(1–naphthoyl)indole, 3-(2-naphthoyl)indole, 1H–indol–3–yl–(1–naphthyl)methane or 1H-indol-3-yl-(2-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

• (i) Any compound structurally derived from 3–(1–naphthoyl)pyrrole or 3-(2-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

• (j) Any compound structurally derived from 1–(1–naphthylmethylene)indene or 1-(2-naphthylmethylene)indene by substitution at the 3–position of the indene ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.

• (k) Any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

• (l) any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.

• (la) Any compound structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

• (lb) Any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent.

• (lc) Any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent.

• (ld) Any compound (not being a compound for the time being specified in sub-paragraphs (h) to (lc) above) structurally related to 1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the four sub-structures, that is to say the indole ring, the pentyl substituent, the methanone linking group and the naphthyl ring, are linked together in a similar manner, whether or not any of the sub-structures have been modified, and whether or not substituted in any of the linked sub-structures with a benzyl or phenyl group and whether or not such compound is further substituted to any extent with alkyl, alkenyl, alkoxy, halide, haloalkyl or cyano substituents and, where any of the sub-structures have been modified, the modifications of the sub-structures are limited to any of the following, that is to say—

• (i) replacement of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole, benzimidazole, pyrrolo[2,3-b]pyridine, pyrrolo[3,2-c]pyridine or pyrazolo[3,4-b]pyridine;

• (ii) replacement of the pentyl substituent with alkyl, alkenyl, benzyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl or (tetrahydropyran-4-yl)methyl;

• (iii) replacement of the methanone linking group with an ethanone, carboxamide, carboxylate, methylene bridge or methine group;

• (iv) replacement of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantyl, cycloalkyl, cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl, 1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, 1-amino-1-oxopropan-2-yl, 1-hydroxy-1-oxopropan-2-yl, piperidinyl, morpholinyl, pyrrolidinyl, tetrahydropyranyl or piperazinyl;

• (m) Any compound (not being bupropion, diethylpropion, pyrovalerone or a compound for the time being specified in sub–paragraph (a) above) structurally derived from 2–amino–1–phenyl–1–propanone by modification in any of the following ways, that is to say—

• (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;

• (ii) by substitution at the 3–position with an alkyl substituent;

• (iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.

• (n) Any compound structurally derived from 2–aminopropan–1–one by substitution at the 1-position with any monocyclic, or fused‑polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say—

• (i) by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

• (ii) by substitution at the 3–position with an alkyl substituent;

• (iii) by substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.

• (o) Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say,

• (i) by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups;

• (ii) by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group;

• (iii) by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group.

• (p) 1-Phenylcyclohexylamine or any compound (not being eticyclidine, ketamine, phencyclidine, rolicyclidine, tenocyclidine or tiletamine) structurally derived from 1-phenylcyclohexylamine or 2-amino-2-phenylcyclohexanone by modification in any of the following ways, that is to say,

• (i) by substitution at the nitrogen atom to any extent by alkyl, alkenyl or hydroxyalkyl groups, or replacement of the amino group with a 1-piperidyl, 1-pyrrolidyl or 1-azepyl group, whether or not the nitrogen containing ring is further substituted by one or more alkyl groups;

• (ii) by substitution in the phenyl ring to any extent by amino, alkyl, hydroxy, alkoxy or halide substituents, whether or not further substituted in the phenyl ring to any extent;

• (iii) by substitution in the cyclohexyl or cyclohexanone ring by one or more alkyl substituents;

• (iv) by replacement of the phenyl ring with a thienyl ring.

• (q) Any compound (not being benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine) structurally derived from mescaline, 4-bromo-2,5-dimethoxy-α-methylphenethylamine, 2,5-dimethoxy-α,4-dimethylphenethylamine, N-hydroxytenamphetamine, or a compound specified in sub-paragraph (c) or (d) above, by substitution at the nitrogen atom of the amino group with a benzyl substituent, whether or not substituted in the phenyl ring of the benzyl group to any extent;

• (r) Any compound (not being a compound for the time being specified in sub- paragraph (c) above) structurally derived from 1-benzofuran, 2,3-dihydro-1-benzofuran, 1H-indole, indoline, 1H-indene, or indane by substitution in the 6-membered ring with a 2-ethylamino substituent whether or not further substituted in the ring system to any extent with alkyl, alkoxy, halide or haloalkyl substituents and whether or not substituted in the ethylamino side-chain with one or more alkyl substituents.

• (s) any compound (not being a compound for the time being specified in sub-paragraph (a) above) with a maximum molecular mass of 500 atomic mass units and structurally derived from 2-(2-benzyl-benzimidazol-1-yl)ethanamine by modification in any of the following ways, that is to say—

• (i) by substitution at the nitrogen of the ethanamine to any extent by alkyl substituents containing up to three carbon atoms or alkenyl substituents containing up to three carbon atoms or by inclusion of the nitrogen atom (and no other atoms of the side chain) in a cyclic structure;

• (ii) by substitution in the phenyl ring of the benzyl system to any extent by alkyl or haloalkyl containing up to six carbon atoms, alkoxy or haloalkoxy containing up to five carbon atoms, acetyloxy, hydroxy, cyano, halogen, thioalkyl containing up to five carbon atoms or alkylsulphonyl containing up to five carbon atoms;

• (iii) by substitution at the 5- or 6- positions of the benzimidazole system by nitro, acetyl, cyano, methoxy, trifluoromethyl, trifluoromethoxy or halogen substituents;

• (iv) by substitution at the benzylic carbon by a methyl group;

• (v) by replacement of the benzylic carbon by a nitrogen, oxygen or sulphur atom;

• (vi) by substitution in the phenyl ring of the benzyl system by an ethoxy group linked back to the phenyl ring to form a dihydrobenzofuran structure;

• (vii) by replacement of the phenyl ring of the benzyl system by methylenedioxyphenyl.

2

Any stereoisomeric form of a substance specified in paragraph 1.

3

Any ester or ether of a substance specified in paragraph 1 (not being 2-((dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol) or paragraph 2.

4

Any salt of a substance specified in any of paragraphs 1 to 3.

5

Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.

SCHEDULE 2 — CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 16A, 18, 19, 20, 21, 23, 26 AND 27

1

The following substances and products, namely—

• Acetorphine

• Alfentanil

• Allylprodine

• Alphacetylmethadol

• Alphameprodine

• Alphamethadol

• Alphaprodine

• Amineptine

• Anileridine

• Benzethidine

• Benzylmorphine (3-benzylmorphine)

• Betacetylmethadol

• Betameprodine

• Betamethadol

• Betaprodine

• Bezitramide

• Cannabis-based product for medicinal use in humans

• Carfentanil

• ...

• Cocaine

• Desomorphine

• Dextromoramide

• Diamorphine

• Diampromide

• Diethylthiambutene

• Difenoxin

• Dihydrocodeinone O-carboxymethyloxime

• Dihydroetorphine

• Dihydromorphine

• Dimenoxadole

• Dimepheptanol

• Dimethylthiambutene

• Dioxaphetyl butyrate

• Diphenoxylate

• Dipipanone

• Dronabinol

• Drotebanol

• Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine

• Ethylmethylthiambutene

• ...

• Etorphine

• Etoxeridine

• Fentanyl

• Furethidine

• Hydrocodone

• Hydromorphinol

• Hydromorphone

• 4-Hydroxy-n-butyric acid

• Hydroxypethidine

• Isomethadone

• Ketamine

• Ketobemidone

• Levomethorphan

• Levomoramide

• Levophenacylmorphan

• Levorphanol

• Lisdexamphetamine

• Lofentanil

• Medicinal opium

• Metazocine

• Methadone

• Methadyl acetate

• Methyldesorphine

• Methyldihydromorphine (6-methyldihydromorphine)

• Metopon

• Morpheridine

• Morphine

• Morphine methobromide, morphine N-oxide and other pentavalent nitrogen morphine derivatives

• Myrophine

• Nabilone

• Nicomorphine

• Noracymethadol

• Norlevorphanol

• Normethadone

• Normorphine

• Norpipanone

• Oripavine

• Oxycodone

• Oxymorphone

• Pethidine

• Phenadoxone

• Phenampromide

• Phenazocine

• Phencyclidine

• Phenomorphan

• Phenoperidine

• Piminodine

• Piritramide

• Proheptazine

• Properidine

• Racemethorphan

• Racemoramide

• Racemorphan

• Remifentanil

• Sufentanil

• Tapentadol

• Thebacon

• Thebaine

• Tilidate

• Trimeperidine

• Zipeprol

• 4-Cyano-2-dimethylamino-4,4-diphenylbutane

• 4-Cyano-1-methyl-4-phenylpiperidine

• 2-Methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid

• a-Methylphenethylhydroxylamine

• 1-Methyl-4-phenylpiperidine-4-carboxylic acid

• 4-Phenylpiperidine-4-carboxylic acid ethyl ester

2

Any stereoisomeric form of a substance specified in paragraph 1 not being dextromethorphan or dextrorphan.

3

Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6.

4

Any salt of a substance specified in any of paragraphs 1 to 3.

5

Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.

6

The following substances and products, namely—

7

Any stereoisomeric form of a substance specified in paragraph 6.

8

Any salt of a substance specified in paragraph 6 or 7.

9

Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5.

SCHEDULE 3 — CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15 ..., 16, 18, 22, 23, 24, 26 AND 27

1

The following substances, namely—

• (a)

• Benzphetamine

• 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one

• Buprenorphine

• Cathine

• Chlorphentermine

• Diethylpropion

• Ethchlorvynol

• Ethinamate

• Flunitrazepam

• Gabapentin (1–(aminomethyl)cyclohexaneacetic acid)

• Mazindol

• Mephentermine

• Meprobamate

• Methylphenobarbitone

• Methyprylone

• Midazolam

• Pentazocine

• Phendimetrazine

• Phentermine

• Pipradrol

• Pregabalin ((S)–3–(aminomethyl)-5-methylhexanoic acid)

• Temazepam

• Tramadol

• (b) any 5, 5 disubstituted barbituric acid not being quinalbarbitone.

2

Any stereoisomeric form of a substance specified in paragraph 1 or 3 not being phenylpropanolamine.

3

Any—

• (a) ester or ether of pipradrol; or

• (b) ester of gabapentin (1–(aminomethyl)cyclohexaneacetic acid) or pregabalin ((S)–3–(aminomethyl)-5-methylhexanoic acid).

4

Any salt of a substance specified in any of paragraphs 1 to 3.

SCHEDULE 4

PART I — CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

1

The following substances and products, namely—

• Alprazolam

• Aminorex

• Bromazepam

• Brotizolam

• Camazepam

• Chlordiazepoxide

• 1–(3–chlorophenyl)piperazine

• 1–(3–chlorophenyl)–4–(3–chloropropyl)piperazine

• Clobazam

• Clonazepam

• Clorazepic acid

• Clotiazepam

• Cloxazolam

• Delorazepam

• Diazepam

• Estazolam

• Ethyl loflazepate

• Fencamfamin

• Fenproporex

• Fludiazepam

• Flurazepam

• Halazepam

• Haloxazolam

• ...

• ...

• Ketazolam

• Loprazolam

• Lorazepam

• Lormetazepam

• Medazepam

• Mefenorex

• Mesocarb

• ...

• Nimetazepam

• Nitrazepam

• Nordazepam

• Oxazepam

• Oxazolam

• Pemoline

• Pinazepam

• Prazepam

• Pyrovalerone

• Remimazolam

• Tetrazepam

• Triazolam

• Xylazine

• N-Ethylamphetamine

• Zaleplon

• Zolpidem

• Zopiclone

2

Any stereoisomeric form of a substance specified in paragraph 1.

3

Any salt of a substance specified in paragraph 1 or 2.

4

Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.

PART II — Controlled Drugs Excepted From the Prohibition on Possession; Excluded from the Application of Offences Arising from the Prohibition on Importation and Exportation when Carried Out in Person for Administration to That Person; and Subject to the Requirements of Regulations 22, 23, 26 and 27

1

The following substances, namely—

• 5α–Androstane–3,17–diol

• Androst-4-ene-3,17-diol

• 1–Androstenediol

• 1–Androstenedione

• 4-Androstene-3, 17-dione

• 5–Androstenedione

• 5-Androstene-3, 17 diol

• Atamestane

• Bolandiol

• Bolasterone

• Bolazine

• Boldenone

• Boldione

• Bolenol

• Bolmantalate

• Calusterone

• 4-Chloromethandienone

• Clostebol

• Danazol

• Desoxymethyltestosterone

• Dienedione (estra-4, 9-diene-3,17-dione)

• Drostanolone

• Enestebol

• Epitiostanol

• Ethyloestrenol

• Fluoxymesterone

• Formebolone

• Furazabol

• Gestrinone

• 3–Hydroxy–5α–androstan–17–one

• Mebolazine

• Mepitiostane

• Mesabolone

• Mestanolone

• Mesterolone

• Methandienone

• Methandriol

• Methenolone

• Methyltestosterone

• Metribolone

• Mibolerone

• Nandrolone

• 19–Norandrostenedione

• 19-Nor-4-Androstene-3, 17-dione

• 19-Nor-5-Androstene-3, 17 diol

• 19–Norandrosterone

• Norboletone

• Norclostebol

• Norethandrolone

• 19–Noretiocholanolone

• Ovandrotone

• Oxabolone

• Oxandrolone

• Oxymesterone

• Oxymetholone

• Prasterone

• Propetandrol

• Prostanozol

• Quinbolone

• Roxibolone

• Silandrone

• Stanolone

• Stanozolol

• Stenbolone

• Testosterone

• Tetrahydrogestrinone

• Thiomesterone

• Trenbolone

2

Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -

• (a) by further substitution at position 17 by a methyl or ethyl group;

• (b) by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;

• (c) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;

• (d) by fusion of ring A with a heterocyclic system.

3

Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule.

4

The following substances, namely—

• Chorionic Gonadotrophin (HCG)

• Clenbuterol

• Non-human chorionic gonadotrophin

• Somatotropin

• Somatrem

• Somatropin

• Zeranol

• Zilpaterol

5

Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule.

6

Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule.

7

Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5.

SCHEDULE 5 — CONTROLLED DRUGS EXCEPTED FROM THE PROHIBITION ON IMPORTATION, EXPORTATION AND POSSESSION (APART FROM NITROUS OXIDE) AND SUBJECT TO THE REQUIREMENTS OF REGULATIONS 24 AND 26

1

• (1) Any preparation of one or more of the substances to which this paragraph applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.

• (2) The substances to which this paragraph applies are acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, nicocodine, nicodicodine (6-nicotinoyldihydrocodeine), norcodeine and pholcodine and their respective salts.

2

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3

Any preparation of medicinal opium or of morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.

4

Any preparation of dextropropoxyphene, being a preparation designed for oral administration, containing not more than 135 milligrams of dextropropoxyphene (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.

5

Any preparation of difenoxin containing, per dosage unit, not more than 0.5 milligrams of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin.

6

Any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 milligrams of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate.

7

Any preparation of propiram containing, per dosage unit, not more than 100 milligrams of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose.

8

Any powder of ipecacuanha and opium comprising—

• 10% opium, in powder,

• 10% ipecacuanha root, in powder, well mixed with

• 80% of any other powdered ingredient containing no controlled drug.

9

Any mixture containing one or more of the preparations specified in paragraphs 1 to 8, being a mixture of which none of the other ingredients is a controlled drug.

SCHEDULE 6 — FORM OF REGISTER

PART I — Entries to be made in case of obtaining

Date on which supply received	Name	Address	Amount obtained	Form in which obtained
	of person or firm from whom obtained	of person or firm from whom obtained

PART II — Entries to be made in case of supply

Date on which transaction effected	Name	Address	Particulars as to licence or authority of person or firm supplied to be in possession	Amount supplied	Form in which supplied
	of person or firm supplied	of person or firm supplied

SCHEDULE 7 — REGULATIONS REVOKED

Regulations revoked	References
The Misuse of Drugs Regulations 1985	S.I. 1985/2066
The Misuse of Drugs (Amendment) Regulations 1986	S.I. 1986/2330
The Misuse of Drugs (Amendment) Regulations 1988	S.I. 1988/916
The Misuse of Drugs (Amendment) Regulations 1989	S.I. 1989/1460
The Misuse of Drugs (Amendment) Regulations 1990	S.I. 1990/2630
The Misuse of Drugs (Amendment) Regulations 1995	S.I. 1995/2048
The Misuse of Drugs (Amendment No. 2) Regulations 1995	S.I. 1995/3244
The Misuse of Drugs (Amendment) Regulations 1996	S.I. 1996/1597
The Misuse of Drugs (Amendment) Regulations 1998	S.I. 1998/882
The Misuse of Drugs (Amendment) Regulations 1999	S.I. 1999/1404

Signed

Bob Ainsworth — Parliamentary Under-Secretary of State — 2001-12-13

Explanatory note

(This note is not part of the Regulations)

Footnotes

Chorionic Gonadotrophin (HCG)

Clenbuterol

Non-human chorionic gonadotrophin

Somatotropin

Somatrem

Somatropin

Editorial notes